Scrip News 2 weeks ago

Elan/Biogen Idec update Tysabri's US label

Today Asher Mullard Elan and Biogen Idec have updated the US label of their multiple sclerosis drug Tysabri (natalizumab) to re-emphasise that it carries a risk of inducing the rare, but potentially fatal, brain infection progressive... Full Article at Scrip News

Related Topics:

  1. US Food and Drug Administration
  2. Food and Drug Administration
  3. Ian Hunter

Related Articles

  1. Tysabri label gets updated PML risk info
    2 weeks ago

    As expected, Biogen Idec and Elan have amended the label of their multiple sclerosis med Tysabri. Full Article at FiercePharma

  2. PharmaTimes logo
    'Benign' label change for Elan/Biogen’s Tysabri
    2 weeks ago

    09 November 2009 Elan Corp and partner Biogen Idec have made changes to the label on Tysabri to reflect the increased risk of a rare and potentially fatal brain disease when the multiple sclerosis blockbuster is taken over a... Full Article at PharmaTimes

  3. Boston Globe logo
    New label says Tysabri risks increase over time
    2 weeks ago

    NEW YORK - A brain infection linked to Biogen Idec Inc. and Elan Corp.’s Tysabri is more likely to occur the longer patients use the multiple sclerosis drug, new prescribing information says. Full Article at Boston Globe

Related Quotes

  1. These new cases are likely to alarm physicians whose comfort with the product had been increasing in recent months, and should catalyze academic and regulatory discussions about more active risk mitigation strategies
    SOURCE: Bloomberg.com 1 month ago
  2. If the rate creeps substantially above 1 out of 1,000, it is possible that regulatory agencies may consider more severe measures
    SOURCE: Bloomberg.com 1 month ago
(What's this?)
  1. Are you a Publisher?

    We built Daylife.com using our SmartMedia Services platform, which can give you thousands of content-rich, advertiser-friendly pages (like this one) on any topic and with full editorial control. Learn More »

    Our Customers
    prev
    next
  2. Our Products
    Daylife Select

    A point & click tool to create dynamic content portals. Learn More »

  3. Daylife API

    Unlimited smart, customizable content to suit any publisher. Learn More »

  4. Enterprise API

    Use the Daylife Platform to distribute content across your sites. Learn More »

  5. SmartContext

    Weave the web's best content into your own. Learn More »

Browse More Photos

Daylife is the web's largest archive of news photos

  1. FILE - In this Oct. 11, 2007 file photo, activist investor Carl Icahn speaks at the World Business Forum in New York.
  2. "Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of DuraSeal(TM) spine sealant, the first product approved by the FDA for intra-operative sealing of the dural membrane during spine procedures."
  3. WASHINGTON - JUNE 12: University of Florida's Emerging Pathogens Institute Director Glenn Morris testifies before the House Subcommittee on Oversight and Investigations June 12, 2008 in Washington, DC.
  4. WASHINGTON - APRIL 22: Commissioner of the Food and Drug Administration Andrew von Eschenbach testifies during a hearing before the Subcommittee on Oversight and Investigations of the House Energy & Commerce Committee April 22, 2008 on Capitol Hill in Washington, DC.
  5. Division Director for the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) Ms. Fan Huihong (C) listens to questions during a briefing on the drug Heparin at the Chinese Embassy in Washington, DC, April 21, 2008.

Cast of Characters

  1. US Food and Drug Administration
  2. Food and Drug Administration Food and Drug Administration
  3. Nasdaq Stock Market, Inc. Nasdaq Stock Market, Inc.
  4. Ian Hunter
  5. European Union European Union